Friday, July 10, 2026

pharma · No medical condition. · Breast cancer

George Institute for

George Institute is a pharma organization headquartered in KOLKATA, IN. Primary therapeutic focus areas include No medical condition., Breast cancer, Metastatic colorectal cancer, Prostate Cancer, advanced/metastatic HER

Sydney, NSW 2042, AU HQ
1999 Founded
841 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Sydney, NSW 2042, AU
Founded
1999
Employees
841
Programs
406
Drugs
522
Patents
0
Clinical program

VHIO24001

Phase 1 · other · Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

VHIO24001 for Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+) is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).

Internal code VHIO24001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
The George Institute
Phase
Phase 1
Modality
other
Indication
Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)
Status
active
Trials
1